ArticleCancers2025

KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas.

Chiara Tarantelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.